期刊
METABOLITES
卷 11, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/metabo11120812
关键词
metabolomics; autoimmune disease; pharmacometabolomics
This paper outlines recent advances in metabolomics research of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus, describing newly discovered biomarkers and metabolic mechanism studies for these diseases. It also presents studies elucidating the metabolic mechanisms underlying these diseases and summarizes biomarker studies aimed at predicting personalized medicine and drug response.
The metabolomics approach represents the last downstream phenotype and is widely used in clinical studies and drug discovery. In this paper, we outline recent advances in the metabolomics research of autoimmune diseases (ADs) such as rheumatoid arthritis (RA), multiple sclerosis (MuS), and systemic lupus erythematosus (SLE). The newly discovered biomarkers and the metabolic mechanism studies for these ADs are described here. In addition, studies elucidating the metabolic mechanisms underlying these ADs are presented. Metabolomics has the potential to contribute to pharmacotherapy personalization; thus, we summarize the biomarker studies performed to predict the personalization of medicine and drug response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据